AzTrials
AzTrials

Colorectal Cancer ScreeningMATCHESNCT06745895

Multilevel Action Toward Colorectal Cancer and Hepatitis C Education and Screening

A study testing MATCHES in people with Colorectal Cancer Screening and Hepatitis C Virus, run by H. Lee Moffitt Cancer Center and Research Institute at 1 site in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This innovative Multilevel Action Toward Colorectal Cancer (CRC) and Hepatitis C Virus (HCV) Education and Screening (MATCHES) intervention aims to promote concurrent HCV and CRC screening among FQHC patients ages 45-75. Read more about this study

Who is it for?
Ages 45 to 75 yearsHealthy volunteers can take part
What is being tested?
MATCHES
Could I receive a placebo?
No, everyone receives an active treatment
How many people
350 participants
Where
1 siteUnited States
Study dates
21 Oct 2024to 30 Apr 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 45 to 75 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Participants must be receiving care at one of the participating FQHC clinics.
  • Participants must be 45-75 years of age.
  • Participants must not be up to date with Colorectal Cancer (CRC) screening recommendations such as no colonoscopy in the past 10 years, occult blood test in the past 12 months.
  • Participants must never have had Hepatitis C Virus (HCV) antibody screening.
  • Participants must be able to read, write, and understand English or Spanish.
  • Participants must have no personal history of CRC or current presumptive CRC symptoms such as unresolved rectal bleeding or abdominal pain/bloating.
Show all 13Show fewer
  • Participants must be at average risk for CRC (no hereditary CRC syndromes such as lower gastrointestinal (GI) bleeding, persistent diarrhea, bloating, or lower GI pain, no strong family history of CRC).
  • Participants must be asymptomatic for HCV.
  • Participants receiving intervention materials must be able and willing to complete surveys and receive the patient level intervention.
  • Participants completing qualitative interviews must be willing to complete a remote interview via phone or teleconference software such as ZOOM.
  • Participants completing qualitative interviews must be willing to be audio recorded.
  • Participants recruited for qualitative interviews only (did not receive MATCHES intervention materials) must have a clinic visit within prior two months.
  • All Participants must be able to provide informed consent.

Who cannot join

  • Participants that do not meet all Inclusion Eligibility requirements will be excluded.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Carol Boxtha contact

813-745-8963

Carol.Boxtha@Moffitt.org

Shannon Christy, PhD contact

United States1 site, 1 recruiting

  • Moffitt Cancer Center

    Tampa, Florida, 33612

    Carol Boxtha, 813-745-8963, Carol.Boxtha@Moffitt.org

    Christy Shannon, PhD

    Recruiting

Other trials in United States

About this study

Official title: Multilevel Action Toward Colorectal Cancer and Hepatitis C Education and Screening (MATCHES)

This innovative Multilevel Action Toward Colorectal Cancer (CRC) and Hepatitis C Virus (HCV) Education and Screening (MATCHES) intervention aims to promote concurrent HCV and CRC screening among FQHC patients ages 45-75.

Read the detailed description

While this is a multi-level intervention study, only information related to the patient-level intervention is being reported for the purposes ClinicalTrials.gov.

Being tested
MATCHES
Keywords
Screening, HCV Screening, CRC Screening, Colorectal Cancer (CRC), Hepatitis C Virus (HCV)
Medical subject headings
Hepatitis C, Colorectal Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • MATCHESBehavioural

    Participants will be asked to complete a survey with specific topics including Hepatitis C (HCV) and Colorectal (CRC) knowledge and health beliefs, screening intentions and demographic characteristics.

    Participants will be provided with education intervention materials (for example, a booklet) either in-person or via mail, access to free stool-based CRC screening, and access to free HCV screening.

    Approximately 1-2 weeks after receiving the education materials, participants will be asked to complete a post-intervention survey about the same specific topics (for example, HCV and CRC knowledge, HCV and CRC health beliefs, HCV and CRC screening intentions, healthcare experiences, perceptions of the educational materials) over the phone with a trained study staff.

    Participants with a positive HCV screening and/or CRC screening result will be navigated to follow-up care as needed.

Study groups in NCT06745895
Study groupRoleWhat they receive
Multilevel Action Toward Colorectal Cancer and Hepatitis C Education and Screening (MATCHES)ExperimentalThe MATCHES intervention includes three patient-level intervention strategies that will be rolled out in two waves. Patient-level strategies are: 1) a combined education booklet with information about CRC/CRC screening and HCV infections/liver cancer/HCV screening in English or Spanish, 2) access to free stool-based CRC screening, and 3) access to free HCV antibody testing.
Receives: Behavioral: MATCHES

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Screening Uptake for Hepatitis C Virus (HCV) and Colorectal Cancer (CRC)

    Screening Uptake will be measured by the number of participants who complete both CRC and HCV screening documented via Electronic Health Record (EHR) at 12 months post-intervention.

    Measured: Up to 12 Months

Secondary outcomes (5)

  1. Screening Completion for Hepatitis C Virus (HCV)

    Screening Completion for HCV will be measured by the number of participants who complete HCV Screening at any time during the Study Period.

    Measured: Up to 41 Months

  2. Screening Completion for Colorectal Cancer (CRC)

    Screening Completion for CRC will be measured by the number of participants who complete CRC Screening at any time during the Study Period.

    Measured: Up to 41 Months

  3. Screening Test Results for Hepatitis C (HCV)

    Screening Test Results will be measured as abnormal vs normal

    Measured: Up to 41 Months

  4. Screening Test Results for Colorectal Cancer (CRC)

    Screening Test Results will be measured as abnormal vs normal

    Measured: Up to 41 Months

  5. Completion of repeat CRC Screening

    Completion of any repeat CRC Screening will be measured by the number of participants who repeat CRC Screening during the Study interval.

    Measured: Up to 41 Months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Dec 2024
  2. Study start21 Oct 2024
  3. Primary completionOct 2027 (estimated)
  4. Study completion30 Apr 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Model description
Eligible and enrolled patient participants enrolled in the intervention will receive a theory-informed educational booklet about both Colorectal Cancer (CRC) and Hepatitis C Virus (HCV) screening in English or Spanish, access to free stool-based CRC screening, and access to HCV screening. Implementation outcomes, facilitators, and barriers will be examined.
Masking
None (open label)
Enrolment
350 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06745895
Sponsor's protocol ID
MCC-23232
Acronym
MATCHES
Status last verified
Sep 2026
First submitted
17 Dec 2024
Last updated
16 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Abdulla R, Boxtha C, Courtney EP, Anyanwu OA, Sutton SK, Chung-Bridges K, Kassaye HG, Philippe E, Mudon KA, Frias E, Parras D, Avrilien N, Friedman M, Turner K, Coronado GD, Champion VL, Tobin JN, Vadaparampil ST, Gwede CK, Christy SM. Multilevel Action Toward Colorectal Cancer and Hepatitis C Education and Screening (MATCHES): Study protocol for a hybrid 1 stepped-wedge multibehavioral randomized trial. Contemp Clin Trials. 2026 Apr;163:108256. doi: 10.1016/j.cct.2026.108256. Epub 2026 Feb 13.

    PubMed 41692274

Questions about this trial

What is this clinical trial studying?

A study testing MATCHES in people with Colorectal Cancer Screening and Hepatitis C Virus, run by H. Lee Moffitt Cancer Center and Research Institute at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 13 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 16 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Carol Boxtha (813-745-8963, Carol.Boxtha@Moffitt.org), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Screening Uptake for Hepatitis C Virus (HCV) and Colorectal Cancer (CRC) (time frame: Up to 12 Months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06745895, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Sep 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in